Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Department of Radiation Oncology, Mayo Clinic, Rochester, MN, USA.
Neurol India. 2023 Mar-Apr;71(Supplement):S133-S139. doi: 10.4103/0028-3886.373631.
Pituitary adenomas are benign brain tumors that comprise 10%-20% of all central nervous system neoplasms. In recent years, stereotactic radiosurgery (SRS) has emerged as a highly effective treatment option in the management of functioning and nonfunctioning adenomas. It is associated with tumor control rates frequently ranging from 80% to 90% in published reports. While permanent morbidity is uncommon, potential side effects include endocrine dysfunction, visual field deficits, and cranial nerve neuropathies. In patients where single fraction SRS would pose an unacceptable risk (e.g. large lesion size or close proximity to the optic apparatus), hypofractionated SRS delivered in 1-5 fractions is a potential treatment option; however, available data are limited. A comprehensive literature search of PubMed/MEDLINE, CINAHL, Embase, and the Cochrane Library was conducted to identify articles reporting on the use of SRS in functioning and nonfunctioning pituitary adenomas.
垂体腺瘤是良性脑肿瘤,占所有中枢神经系统肿瘤的 10%-20%。近年来,立体定向放射外科(SRS)已成为功能性和非功能性腺瘤治疗的一种非常有效的选择。在已发表的报告中,其肿瘤控制率通常高达 80%-90%。虽然永久性发病率并不常见,但潜在的副作用包括内分泌功能障碍、视野缺损和颅神经病变。对于单次 SRS 治疗会带来不可接受风险的患者(例如病变较大或靠近视觉器官),1-5 次分割的 SRS 可能是一种潜在的治疗选择;然而,现有数据有限。对 PubMed/MEDLINE、CINAHL、Embase 和 Cochrane Library 进行了全面的文献检索,以确定报道 SRS 在功能性和非功能性垂体腺瘤中应用的文章。